People with preclinical Alzheimer’s disease have notably different gut microbiome features from those without the condition. The distinct gut microbiome features may help physicians detect preclinical Alzheimer’s early for individuals at risk. People with the preclinical condition have normal cognitive ability, while already show the biological evidence of Alzheimer’s in the brain, blood, or the […]
GFAP, a Strong Blood-based Biomarker, Predicted Alzheimer’s Disease at Least 10 Years Before Symptoms Appear
Researchers have found that by evaluating people’s blood levels of glial fibrillary acidic protein (GFAP), together with their cognitive test results and demographic information, they could predict Alzheimer’s disease at least 10 years before the diagnosis. The prediction was more accurate when they considered all these factors together, rather than considering the blood level of GFAP alone. […]
Read Time:
6 Min
Increased Blood Levels of GFAP May Track Alzheimer’s Disease Progression Before Cognitive Symptoms Occur
In a study with people who had normal cognitive ability, researchers found that the blood levels of glial fibrillary acidic protein (GFAP) increased more rapidly in people at risk of future Alzheimer’s disease than those without the risk of the disease. Protein GFAP locates in the cells that support the nerve cells in the central […]
Read Time:
5 Min